8-K: Oragenics Sets New Date for 2024 Annual Shareholder Meeting and Proposal Deadlines
8-K Filing
Oragenics, Inc. announces the rescheduling of its 2024 Annual Meeting of Shareholders to May 16, 2025, and sets a new deadline of March 14, 2025, for shareholder proposals.
Summary
- Oragenics, Inc. has rescheduled its 2024 Annual Meeting of Shareholders for May 16, 2025.
- This change necessitates a new deadline for shareholder proposals intended for inclusion in the company's proxy statement.
- Shareholders must submit proposals by March 14, 2025, to Oragenics' principal executive offices in Sarasota, Florida.
Sentiment
Score: 5
Explanation: The document is a neutral announcement regarding the scheduling of the annual shareholder meeting and proposal deadlines.
Industry Context
The announcement is a routine corporate governance update, ensuring compliance with SEC regulations regarding shareholder meetings and proposal submissions.
Stakeholder Impact
- Shareholders are informed of the new meeting date and proposal submission deadline.
- The company ensures compliance with SEC regulations.
Next Steps
- Shareholders to submit proposals by the specified deadline if they wish to have them included in the proxy statement.
- Oragenics to prepare and distribute the proxy statement for the 2024 Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| 2025-02-17 | Date of the Board of Directors' decision to schedule the 2024 Annual Meeting of Shareholders. |
| 2025-03-14 | Deadline for shareholders to submit proposals for inclusion in the company's 2024 proxy statement. |
| 2025-05-16 | Date of Oragenics' 2024 Annual Meeting of Shareholders. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.